Beloranib
An Efficacy, Safety and Pharmacokinetics Study of Beloranib (ZGN-440 for Injectable Suspension) in Obese Subjects
Zafgen · Phase 2 · Completed · Enrollment 160
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Placebo | Obesity or overweight | n/r | 12 | n/r | n/r |
| 0.3 mg Beloranib | Obesity or overweight | 0.3 mg | 12 | n/r | n/r |
| 0.6 mg Beloranib | Obesity or overweight | 0.6 mg | 12 | n/r | n/r |
| 1.2 mg Beloranib | Obesity or overweight | 1.2 mg | 12 | n/r | n/r |
| 2.4 mg Beloranib | Obesity or overweight | 2.4 mg | 12 | n/r | n/r |
| 3.2 mg Beloranib | Obesity or overweight | 3.2 mg | 12 | n/r | n/r |